FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burd	len
hours per response.	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

issuer that is int	e of equity securities or lended to satisfy the nse conditions of Rule Instruction 10.	f the			
	ress of Reporting Pe	rson *	2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]	5. Relationship of Reporting Person (Check all applicable)	(s) to Issuer
Yorke Justin	<u>1 W</u>		, , ,	X Director	10% Owner
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/27/2023	Officer (give title below)	Other (specify below)
	SA PHARMACE OLA DRIVE, SU	*	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (C X Form filed by One Report Form filed by More than C	ing Person
(Street)				Form filed by More than C	one Reporting Person
HANOVER	MD	21076			
(City)	(State)	(Zip)			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	06/27/2023		M		23,636	A	(1)	56,729	D	
Common Stock								519,890	I	By Richland Fund, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Restricted Stock	\$0	06/27/2023		M			23,636	(1)	(1)	Common Stock	23,636	\$0	0	D	
Restricted Stock	\$0	06/27/2023		A		101,365		(2)	(2)	Common Stock	101,365	\$0	101,365	D	

Explanation of Responses:

- 1. Vesting of time-based restricted shares.
- 2. The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders.

/s/ Justin W. Yorke by Michael B. Kirwan, as Attorney-in-Fact 07/24/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.